Blar i Bergen Open Research Archive på forfatter "Wergeland, Stig"

Viser treff 21-25 av 25

    • Predictors of hospitalization due to infection in rituximab-treated MS patients 

      Karlowicz, Jakob Rishovd; Klakegg, Mattias; Aarseth, Jan Harald; Bø, Lars; Myhr, Kjell-Morten; Torgauten, Hilde Marie; Torkildsen, Øivind; Wergeland, Stig (Journal article; Peer reviewed, 2023)
      Background: Rituximab is extensively used off-label to treat multiple sclerosis (MS), and long-term vigilance for adverse events is needed. This study was conducted to determine frequencies and predictors of hematological ...

    • Real-world discontinuation rate of teriflunomide and dimethyl fumarate in multiple sclerosis 

      Norborg, Hilde; Riise, Trond; Myhr, Kjell-Morten; Torkildsen, Nina Agnethe Grytten; Wergeland, Stig (Journal article; Peer reviewed, 2021)
      Background For patients with MS, medication switches increase the risk of disease reactivation. Objective Compare discontinuation rates due to treatment failure or side effects between teriflunomide and dimethyl ...

    • Safety and efficacy of rituximab as first- and second line treatment in multiple sclerosis – A cohort study 

      Torgauten, Hilde Marie; Myhr, Kjell-Morten; Wergeland, Stig; Bø, Lars; Aarseth, Jan Harald; Torkildsen, Øivind (Journal article; Peer reviewed, 2021-01-31)
      Background Rituximab is increasingly used as off-label therapy in multiple sclerosis (MS). More data are needed on safety and efficacy of rituximab, particularly in cohorts of de novo patients and patients in early therapy ...

    • Safety of breast feeding during rituximab treatment in multiple sclerosis 

      Rød, Brit Ellen; Torkildsen, Øivind; Myhr, Kjell-Morten; Bø, Lars; Wergeland, Stig (Journal article; Peer reviewed, 2022)
      Background There are limited data on the safety of breast feeding during rituximab therapy. Our objective is to determine exposure from breast feeding and biological effects of rituximab in breastfed infants. Methods ...

    • Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study 

      Lie, Ingrid Anne; Kacar, Sezgi; Wesnes, Kristin; Brouwer, Iman; Kvistad, Silje S.; Wergeland, Stig; Holmøy, Trygve; Midgard, Rune; Bru, Alla Nikolajevna S; Edland, Astrid; Eikeland, Randi; Gosal, Sonia; Harbo, Hanne-Cathrin Flinstad; Kleveland, Grethe; Sørenes, Yvonne; Øksendal, Nina; Varhaug, Kristin Nielsen; Vedeler, Christian Alexander; Barkhof, Frederik; Teunissen, Charlotte E.; Bø, Lars; Torkildsen, Øivind Fredvik Grytten; Myhr, Kjell-Morten; Vrenken, Hugo (Journal article; Peer reviewed, 2022)
      Background The predictive value of serum neurofilament light chain (sNfL) on long-term prognosis in multiple sclerosis (MS) is still unclear. Objective Investigate the relation between sNfL levels over a 2-year ...